JP5875975B2 - ロバの乳から分離されたプロバイオティクス微生物 - Google Patents
ロバの乳から分離されたプロバイオティクス微生物 Download PDFInfo
- Publication number
- JP5875975B2 JP5875975B2 JP2012509030A JP2012509030A JP5875975B2 JP 5875975 B2 JP5875975 B2 JP 5875975B2 JP 2012509030 A JP2012509030 A JP 2012509030A JP 2012509030 A JP2012509030 A JP 2012509030A JP 5875975 B2 JP5875975 B2 JP 5875975B2
- Authority
- JP
- Japan
- Prior art keywords
- lactic acid
- acid bacteria
- probiotic lactic
- dna
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000006041 probiotic Substances 0.000 title claims description 60
- 235000018291 probiotics Nutrition 0.000 title claims description 60
- 230000000529 probiotic effect Effects 0.000 title claims description 54
- 235000020250 donkey milk Nutrition 0.000 title description 14
- 244000005700 microbiome Species 0.000 title description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 98
- 241000894006 Bacteria Species 0.000 claims description 71
- 239000004310 lactic acid Substances 0.000 claims description 49
- 235000014655 lactic acid Nutrition 0.000 claims description 49
- 235000013305 food Nutrition 0.000 claims description 32
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 29
- 238000000855 fermentation Methods 0.000 claims description 29
- 230000004151 fermentation Effects 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 13
- 235000013361 beverage Nutrition 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000004060 metabolic process Effects 0.000 claims description 9
- 235000013336 milk Nutrition 0.000 claims description 9
- 239000008267 milk Substances 0.000 claims description 9
- 210000004080 milk Anatomy 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 241000283074 Equus asinus Species 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 5
- 230000005526 G1 to G0 transition Effects 0.000 claims description 4
- 235000021107 fermented food Nutrition 0.000 claims description 4
- 241000589876 Campylobacter Species 0.000 claims description 3
- 241000193403 Clostridium Species 0.000 claims description 3
- 241000186781 Listeria Species 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 35
- 239000003833 bile salt Substances 0.000 description 30
- 241000186660 Lactobacillus Species 0.000 description 19
- 229940039696 lactobacillus Drugs 0.000 description 19
- 229940093761 bile salts Drugs 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 125000001475 halogen functional group Chemical group 0.000 description 11
- 240000006024 Lactobacillus plantarum Species 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000004051 gastric juice Anatomy 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 238000007900 DNA-DNA hybridization Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000000813 microbial effect Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- 241000866650 Lactobacillus paraplantarum Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 5
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000004347 intestinal mucosa Anatomy 0.000 description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 240000006439 Aspergillus oryzae Species 0.000 description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000369 enteropathogenic effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940017800 lactobacillus casei Drugs 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000020185 raw untreated milk Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 3
- 239000003298 DNA probe Substances 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000193755 Bacillus cereus Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 235000020138 yakult Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- PKAUICCNAWQPAU-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)acetic acid;n-methylmethanamine Chemical compound CNC.CC1=CC(Cl)=CC=C1OCC(O)=O PKAUICCNAWQPAU-UHFFFAOYSA-N 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241001468157 Lactobacillus johnsonii Species 0.000 description 1
- 241000186684 Lactobacillus pentosus Species 0.000 description 1
- 241000186612 Lactobacillus sakei Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012192 RiboPure Bacteria Kit Methods 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000006067 antibiotic powder Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000959 cryoprotective effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
上記のような本発明の生きたプロバイオティクス乳酸菌を食品へ接種することと、
接種した食品を、前述のプロバイオティクス乳酸菌の代謝に有利な条件下に置くことと、
少なくとも、106CFU/mlの個体数になるまで、前述の食品を発酵させること。
上記のようなプロバイオティクス乳酸菌を、106CFU/mlの個体数になるまで、発酵させることと、
例えば、エンベロープによって、前述のプロバイオティクス乳酸菌を保護することと、
食品組成物と前述の保護されたプロバイオティクス乳酸菌とを混合すること。
本明細書に記載されたような胃液耐性評価後に、少なくとも75%のCFU/mLが保持されることと、
本明細書に記載されたような胃液及び胆汁酸塩耐性評価後に、少なくとも75%のCFU/mLが保持されることと、
本明細書の疎水性試験における、硫酸アンモニウム0.5M以下、好ましくは硫酸アンモニウム0.1M以下での、顕微鏡のガラス上に可視の微生物の凝集、
本明細書に記載されたように、ハローテストによって測定されたような、即ち、ハローが0.5cm未満、好ましくは0.2cm未満という、他の乳酸菌属に対する低い抗菌活性、および、
本明細書に記載されたように、ハローテストによって測定されたような、即ち、ハローが0.5cmより大きい、好ましくは0.8cm大きいという、緑膿菌、セレウス菌、または大腸菌に対する阻害活性。
クローン 37 DSM 22098
クローン 38 DSM 22099
クローン 48 DSM 22100
クローン 43 DSM 22102
クローン 41 DSM 22101
クローン 32 DSM 23558
クローン 34 DSM 23559
クローン 57 DSM 23560
−0.1M硫酸アンモニウムでの微生物凝集が目視可能:クローン32、37、43及び57
−0.5M硫酸アンモニウムでの微生物凝集が目視可能:クローン34、38、41及び48
−非病原性株:乳酸菌DSM20079、ラクトバチルス・カゼイATCC9595、ラクトバチルス・ブルガリDSM20081、ラクトバチルス・サケイ DSM20494、ラクトバチルス・ラムノサスDSM20711
−病原性のグラム陽性菌:枯草菌GN101、DSM4313及びDSM4384、並びに腸球菌ATCC29212
−病原性のグラム陰性菌:大腸菌(DSM8579)及び緑膿菌(DSM50071)。
クローンは、乳酸菌サケイ20494に対する抗菌活性を示さなかった(非常に低い程度でのクローン57を除く)。
−クローン37、38及び48は、ラクトバチルス・カゼイATCC9595、L.ブルガリカスATCC11842、L.ファーメンタムDSM20052、及びL.ラムノサスDSM20711に対して低い阻害活性を示した。
−クローン41は、L.ファーメンタムDSM20052、L.ラムノサスDSM20711、L.アシドフィルスDSM20079に対して低い阻害活性を示した。
−クローン43は、L.ファーメンタムDSM20052及びL.アシドフィルスDSM20079に対して低い阻害活性を示した。
ND 検出されず
OX 低い阻害活性(ハロ:5mm未満)
X 中間の阻害活性(ハロ:6〜8mm)
XX 離散的阻害活性(ハロ:8〜10mm)
XXX 強い阻害活性(ハロ:10mmより大きい)
−細胞壁合成の阻害剤としてアンピシリン、及びアモキシシリン;
−タンパク質合成の阻害剤として硫酸ゲンタマイシン、リンコマイシン、ストレプトマイシン硫酸塩、テトラサイクリン、クロラムフェニコール及びスピラマイシン;
−核酸合成の阻害剤としてリファミキシン(rifamixin)。
クローン32 同定不十分
クローン34 同定不十分
クローン37 ラクトバチルスプランタラム99.5%という優れた同定
クローン38 疑わしい同定
クローン41 予備的な疑わしい同定
クローン43 予備的な疑わしい同定
クローン48 ラクトバチルスプランタラム99.5%という優れた同定
クローン57 同定不十分
クローン41
細菌(20)ドメイン (一致配列)
Firmicutes(20)門、「桿菌」(20)綱、「ラクトバチルス」(20)目、ラクトバシラセエ(20)科、ラクトバチルス(20)属
0.994 1400 L.パラプランタラム(T)、DSM10667T;A5306297
0.979 1405 L.プランタラム(T)、JCM1149;D79210
0.984 1410 L.ペントサス(T)、JCM1558、D79211
クローン43
細菌(20)ドメイン (一致配列)
「ファーミキューテス」(20)門、「桿菌」(20)綱、「ラクトバチルス」(20)目、ラクトバシラセエ(20)科、ラクトバチルス(20)属
1400 L.パラプランタラム(T);DSM 10667T;AJ306297
0.985 1405 L.プランタラム(T);JCM 1149;D79210
0.990 1410 L.ペントサス(T); JCM 1558;D7921
クローン48
細菌(20)ドメイン (一致配列)
「ファーミキューテス」(20)門、「桿菌」(20)綱、「ラクトバチルス」(20)目、ラクトバシラセエ(20)科、ラクトバチルス(20)属
1.000 L.プランタラム(T);JCM 1 149;D792 10
クローン57
細菌(0/20/5164)ドメイン (選択/一致/総 RDP配列)
「ファーミキューテス」(0/20/1178)門、「桿菌」(0/20/697)綱、「ラクトバチルス」(0/20/289)目、ラクトバシラセエ(0/20/114)科、ラクトバチルス(0/20/104)属
0.987 1400 L.パラプランタラム(T);DSM 10667T;A5306297
0.990 1405 L.プランタラム(T);JCM 1149;D79210
0.994 1410 L.ペントサス(T);JCM 1558; D79211
Claims (8)
- 特にロバの乳から単離され、寄託番号DSM22098、DSM22099、DSM22100、DSM22102、DSM22101、DSM23558、DSM23559、及びDSM23560でDSMZに寄託された菌株から成る群から選択される、プロバイオティクス乳酸菌。
- 少なくとも、
−請求項1に記載の生存可能なプロバイオティクス乳酸菌を食品製品に接種するステップと、
−前記プロバイオティクス乳酸菌が代謝するのに適した条件下に、前記接種した食品製品を置くステップと、
−個体数が、少なくとも106CFU/mL(食品)に到達するまで、前記食品製品を発酵させるステップと、
を含む、食品組成物または飲料組成物の製造プロセス。 - 少なくとも、
−請求項1に記載のプロバイオティクス乳酸菌を、個体数が少なくとも106CFU/mLに到達するまで発酵させるステップと、
−前記プロバイオティクス乳酸菌を保護するステップと、
−前記保護されたプロバイオティクス乳酸菌と食品製品とを混合させるステップと、
を含む、食品組成物または飲料組成物の製造プロセス。 - 発酵が定常期に達した時に発酵を停止する、請求項2または3に記載のプロセス。
- 前記プロバイオティクス乳酸菌をそれらが代謝するのに適した条件下に配置した状態で24時間以内に発酵を停止する、請求項4に記載のプロセス。
- リステリア、サルモネラ、カンピロバクターまたはクロストリジウムなどの食品の病原体に対して、このような食品病原体の成長の阻害によって発酵食品製品を保護するための、請求項1に記載のプロバイオティクス乳酸菌の使用。
- 発酵の間に酪酸を製造するための、請求項1に記載のプロバイオティクス乳酸菌の使用であって、前記発酵が前記プロバイオティクス乳酸菌を利用する、使用。
- 適した条件下で請求項1に記載のプロバイオティクス乳酸菌を発酵させるステップと、前記プロバイオティクス乳酸菌によって発酵されている間に製造された酪酸を収集するステップとを含む、酪酸を製造するための方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09159379.8 | 2009-05-05 | ||
EP09159379A EP2248908A1 (en) | 2009-05-05 | 2009-05-05 | Probiotic microorganisms isolated from donkey milk |
PCT/EP2010/056117 WO2010128084A1 (en) | 2009-05-05 | 2010-05-05 | Probiotic microorganisms isolated from donkey milk |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012525828A JP2012525828A (ja) | 2012-10-25 |
JP5875975B2 true JP5875975B2 (ja) | 2016-03-02 |
Family
ID=41066671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012509030A Active JP5875975B2 (ja) | 2009-05-05 | 2010-05-05 | ロバの乳から分離されたプロバイオティクス微生物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120128821A1 (ja) |
EP (2) | EP2248908A1 (ja) |
JP (1) | JP5875975B2 (ja) |
CN (1) | CN102753701B (ja) |
CA (1) | CA2761141C (ja) |
ES (1) | ES2562702T3 (ja) |
WO (1) | WO2010128084A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20110791A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri in grado di metabolizzare gli ossalati. |
ITMI20110792A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia. |
ITMI20110793A1 (it) | 2011-05-09 | 2012-11-10 | Probiotical Spa | Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati. |
ITRM20110475A1 (it) * | 2011-09-09 | 2013-03-10 | Probiotical Spa | Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e |
WO2013130624A2 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Probiotic compositions and methods |
ITRM20120170A1 (it) | 2012-04-19 | 2013-10-20 | Dicofarm Spa | "alimento a base di latte d'asina fortificato per neonati pretermine e/o a termine con allergia o intolleranza alle proteine del latte vaccino e relativo metodo di preparazione" |
ITMI20130793A1 (it) | 2013-05-14 | 2014-11-15 | Probiotical Spa | Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti. |
ITMI20131690A1 (it) * | 2013-10-14 | 2015-04-15 | Consiglio Nazionale Ricerche | Composizione alimentare. |
CN107151638B (zh) * | 2017-05-25 | 2020-05-08 | 中驭(北京)生物工程有限公司 | 一株改善肝功能的植物乳杆菌zy001及其在发酵乳中的应用 |
TR201712406A2 (tr) | 2017-08-21 | 2019-03-21 | Nanomik Biyoteknoloji A S | Probiyotik Yüklü Mikrokapsüller Ve Bunların Üretimi |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1927813A (en) * | 1928-10-03 | 1933-09-19 | Commercial Solvents Corp | Process of accelerating the production of butyric acid by fermentation |
DK0760848T3 (da) | 1994-05-26 | 1998-09-23 | Bracco Spa | Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf |
EP0948262A1 (fr) | 1996-12-24 | 1999-10-13 | Societe Des Produits Nestle S.A. | Produit laitier fermente |
AU2005282182A1 (en) * | 2004-09-10 | 2006-03-16 | Medela Holding Ag | Human milk fortifiers and methods for their production |
US20060078546A1 (en) * | 2004-10-07 | 2006-04-13 | Anders Zachrisson | Use of lactic acid bacteria to reduce sick time |
CN101081045A (zh) * | 2006-05-30 | 2007-12-05 | 张保钢 | 酸羊奶及其制备方法 |
JP5081242B2 (ja) * | 2006-08-04 | 2012-11-28 | バイオニア コーポレイション | 人間母乳から分離したプロバイオティック活性、及び体重増加抑制活性を有する乳酸菌 |
CN101283703B (zh) * | 2008-05-13 | 2011-05-18 | 孟克 | 全脂酸马奶粉的制备方法 |
-
2009
- 2009-05-05 EP EP09159379A patent/EP2248908A1/en not_active Withdrawn
-
2010
- 2010-05-05 US US13/319,124 patent/US20120128821A1/en not_active Abandoned
- 2010-05-05 EP EP10718580.3A patent/EP2427566B1/en active Active
- 2010-05-05 WO PCT/EP2010/056117 patent/WO2010128084A1/en active Application Filing
- 2010-05-05 CA CA2761141A patent/CA2761141C/en active Active
- 2010-05-05 ES ES10718580.3T patent/ES2562702T3/es active Active
- 2010-05-05 JP JP2012509030A patent/JP5875975B2/ja active Active
- 2010-05-05 CN CN201080019943.9A patent/CN102753701B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2248908A1 (en) | 2010-11-10 |
CA2761141C (en) | 2020-08-04 |
EP2427566A1 (en) | 2012-03-14 |
CN102753701A (zh) | 2012-10-24 |
ES2562702T3 (es) | 2016-03-07 |
CN102753701B (zh) | 2015-01-21 |
US20120128821A1 (en) | 2012-05-24 |
EP2427566B1 (en) | 2015-10-28 |
JP2012525828A (ja) | 2012-10-25 |
WO2010128084A1 (en) | 2010-11-11 |
CA2761141A1 (en) | 2010-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5875975B2 (ja) | ロバの乳から分離されたプロバイオティクス微生物 | |
Wu et al. | Isolation and preliminary probiotic selection of lactobacilli from koumiss in Inner Mongolia | |
Kumar et al. | Characterization of Lactobacillus isolated from dairy samples for probiotic properties | |
Nath et al. | In vitro screening of probiotic properties of Lactobacillus plantarum isolated from fermented milk product | |
Yerlikaya et al. | In vitro characterisation of probiotic properties of Enterococcus faecium and Enterococcus durans strains isolated from raw milk and traditional dairy products | |
JP2742962B2 (ja) | 腸定着ラクトバシラス | |
Iyer et al. | Probiotic properties of folate producing Streptococcus thermophilus strains | |
Braïek et al. | Biotechnological potential, probiotic and safety properties of newly isolated enterocin-producing Enterococcus lactis strains | |
JP2014526242A (ja) | 大腸菌の様々なバイオタイプおよびクロストリジウム菌の様々なバイオタイプの増殖を阻害/低減する乳酸菌および/またはビフィズス菌の株 | |
EP2684469A1 (en) | Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth | |
KR102036275B1 (ko) | 항-염증 활성이 우수한 페디오코커스 악시딜락티시 ldtm 5201 신균주(kctc 13563bp) | |
Sadrani et al. | Screening of potential probiotic Lactobacillus strains isolated from fermented foods, fruits and of human origin | |
El-Sayed et al. | Identification of Lactobacillus strains from human mother milk and cottage cheese revealed potential probiotic properties with enzymatic activity | |
KR101098946B1 (ko) | 신규한 락토바실러스 살리바리우스 균주 및 이를 함유하는 사료첨가제 조성물 | |
KR101201338B1 (ko) | 신규 락토바실러스 루테리 및 이를 포함하는 사료첨가제 조성물 | |
Ugarte et al. | Nonstarter lactobacilli isolated from soft and semihard Argentinean cheeses: genetic characterization and resistance to biological barriers | |
KR100825500B1 (ko) | 경구 운반체의 개발을 위한 돼지 유래 신규 유산균 및 이의용도 | |
Pato | Bile and acid tolerance of lactic acid bacteria isolated from dadih and their antimutagenicity against mutagenic heated tauco | |
Abdel-Haleem et al. | Potential anti-hypercholesterolemic activity and acidogenic ability of probiotic lactic acid bacteria isolated from camel milk | |
LIMA et al. | Coalho cheese as source of probiotic lactic acid bacteria. | |
Lee et al. | Potential probiotic properties of Lactococcus lactis NK34 isolated from jeotgal | |
Akmal et al. | Probiotic and antioxidant potential of the Lactobacillus spp. isolated from artisanal fermented pickles. Fermentation 2022; 8: 328 | |
JP2002119276A (ja) | ラクトバチルス・ラムノーサス株及びその使用 | |
Azuma et al. | Lactobacillus casei NY1301 increases the adhesion of Lactobacillus gasseri NY0509 to human intestinal Caco-2 cells | |
Temirova | Antibiotic resistance and probiotic properties of lactic acid bacteria isolated from camel milk and shubat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130507 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141216 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150227 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150327 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151124 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160120 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5875975 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |